Director at Dare Bioscience (NASDAQ: DARE) receives 10,000 stock options grant

Rhea-AI Filing Summary

Dare Bioscience, Inc. director Robin Joan Steele received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036.

The option will vest in full on the earlier of the first anniversary of the June 11, 2026 grant date or immediately prior to the company’s first annual meeting of stockholders occurring after that date, subject to Steele’s continued service as a director. The option also becomes fully exercisable upon a change in control of the company. Following this grant, Steele holds 10,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Steele Robin Joan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 10,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 10,000 options Exercise price: $2.03 per share Expiration date: June 11, 2036 +2 more

5 metrics

Options granted 10,000 options Stock Option (right to buy) grant to director

Exercise price $2.03 per share Exercise price of options on common stock

Expiration date June 11, 2036 Option expiration for director grant

Underlying shares 10,000 shares Common stock underlying the stock options

Post-grant option holdings 10,000 options Total options held following transaction

Key Terms

Stock Option (right to buy), grant/award acquisition, change in control, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

change in control financial

"will become exercisable in full upon a change in control of the issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

annual meeting of stockholders financial

"immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Steele Robin Joan

(Last) (First) (Middle)

3655 NOBEL DRIVE

SUITE 260

(Street)

SAN DIEGO CALIFORNIA 92122

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dare Bioscience, Inc. [ DARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.03	06/11/2026		A		10,000		(1)	06/11/2036	Common stock	10,000	$0	10,000	D

Explanation of Responses:

1. This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.

Remarks:

	/s/ Sabrina Martucci Johnson, Attorney-in-fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Dare Bioscience (DARE) disclose about director Robin Joan Steele?

Dare Bioscience disclosed that director Robin Joan Steele received a grant of stock options for 10,000 common shares. These options are a form of equity compensation and give her the right to buy shares at a fixed exercise price in the future.

How many stock options were granted to the Dare Bioscience (DARE) director?

Robin Joan Steele was granted stock options on 10,000 shares of Dare Bioscience common stock. This award represents her entire option position reported in the filing, with 10,000 options shown as held directly following the transaction.

What is the exercise price of the new Dare Bioscience (DARE) stock options?

The stock options granted to director Robin Joan Steele have an exercise price of $2.03 per share. This means she can later purchase Dare Bioscience common stock at $2.03, regardless of the market price when she exercises the options.

When do the Dare Bioscience (DARE) options granted to Robin Joan Steele vest?

The options vest in full on the earlier of the first anniversary of the June 11, 2026 grant date or immediately before the first annual stockholder meeting after that date. Vesting is also conditioned on Steele’s continued service as a director during this period.

When do Robin Joan Steele’s Dare Bioscience (DARE) options expire?

The stock options granted to Robin Joan Steele expire on June 11, 2036. After this expiration date, any unexercised options will lapse, and she will no longer be able to purchase Dare Bioscience shares at the $2.03 exercise price.

How does a change in control affect the Dare Bioscience (DARE) options?

The filing states the options become fully exercisable upon a change in control of Dare Bioscience. This means if the company undergoes a qualifying control change, Steele’s options can be exercised in full, regardless of their normal vesting schedule.